JPM 2016: Cipla Shapes Respiratory Build-Up
This article was originally published in PharmAsia News
Executive Summary
Around a quarter of Cipla's top 50 R&D projects currently underway are in the respiratory segment and the Indian firm says it aims to launch its own differentiated respiratory and oncology pipeline in the US in the "near future."
You may also be interested in...
Cipla, Sandoz Gearing For Seretide Challenge In Australia?
The Australian respiratory market seems set for a potential spurt in activity. Cipla and Sandoz appear to be gearing to take their respective competing versions of GlaxoSmithKline’s Seretide to Australia, piling up pressure on the UK multinational’s therapy there.
Cipla, Sandoz Gearing For Seretide Challenge In Australia?
The Australian respiratory market seems set for a potential spurt in activity. Cipla and Sandoz appear to be gearing to take their respective competing versions of GlaxoSmithKline’s Seretide to Australia, piling up pressure on the UK multinational’s therapy there.
Cipla 2.0: ‘Disproportionate’ US Growth, Getting The Profit Curve Right
Cipla is planning an ambitious growth trajectory, aiming to propel its US business “towards a $1bn generic enterprise” and develop a strong specialty franchise focused on its traditional stronghold, the respiratory segment, and the CNS space.